Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts have given Pelthos a consensus "Moderate Buy" rating (5 buys, 1 hold) with an average 12‑month price target of $55.00, versus a mid‑day share price of $21.01, implying substantial analyst‑implied upside.
• Pelthos is a clinical‑stage biotech developing pain therapies that target the sodium channel NaV1.7, a genetically validated pain receptor, which is the company’s primary therapeutic focus.
• The stock is small and volatile (market cap ~$70.6M, beta 3.87, negative P/E), and institutions own roughly 77.96% of shares with several hedge funds recently increasing stakes.

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $55.00.

Several analysts recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price objective on shares of Pelthos Therapeutics in a research note on Thursday, March 19th. Zacks Research upgraded Pelthos Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 24th. Piper Sandler initiated coverage on Pelthos Therapeutics in a research report on Friday, February 27th. They issued an "overweight" rating and a $48.00 price target for the company. Oppenheimer lifted their price objective on Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an "outperform" rating in a research report on Friday, March 20th. Finally, Roth Mkm lowered their price objective on Pelthos Therapeutics from $57.00 to $55.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th.

Pelthos Therapeutics Price Performance

Shares of NYSEAMERICAN PTHS remained flat at $21.01 during mid-day trading on Wednesday. 3,300 shares of the stock were exchanged, compared to its average volume of 4,010. The company has a fifty day simple moving average of $23.06. The company has a current ratio of 2.05, a quick ratio of 1.15 and a debt-to-equity ratio of 0.81. The company has a market cap of $70.59 million, a price-to-earnings ratio of -1.01 and a beta of 3.87. Pelthos Therapeutics has a 1-year low of $9.00 and a 1-year high of $54.29.

Institutional Investors Weigh In On Pelthos Therapeutics

Hedge funds have recently modified their holdings of the company. Persistent Asset Partners Ltd lifted its stake in Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company's stock worth $186,000 after purchasing an additional 3,604 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Pelthos Therapeutics in the fourth quarter valued at $343,000. Geode Capital Management LLC raised its holdings in shares of Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company's stock valued at $422,000 after buying an additional 3,295 shares during the period. Knott David M Jr lifted its stake in Pelthos Therapeutics by 215.5% during the 4th quarter. Knott David M Jr now owns 19,281 shares of the company's stock worth $598,000 after acquiring an additional 13,169 shares in the last quarter. Finally, Diadema Partners LP boosted its holdings in Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company's stock valued at $775,000 after acquiring an additional 14,502 shares during the period. Hedge funds and other institutional investors own 77.96% of the company's stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.